Introduction
Greater than 70 % of poor people live in rural and remote regions of Africa [1] , often with limited, if any, access to modern healthcare facilities and specialist clinicians. Consequently, it is highly probable that rheumatoid arthritis (RA), which has a prevalence of 1-3 % in developed countries, is substantially underdiagnosed in our continent. Failure to diagnose RA at an early stage not only imposes considerable physical, emotional and socioeconomic hardship on patients, but also increases the demands on national healthcare budgets and facilities due to presentation of patients with late-stage, often therapy-refractory, disease. A twofold approach is necessary to address this problem: firstly, ease of access of patients to specialist rheumatologists and appropriate therapies and secondly, the availability of reliable, cost-effective serodiagnostic procedures, Abstract Early diagnosis of patients with rheumatoid arthritis (RA) optimises therapeutic benefit and the probability of achieving disease remission. Notwithstanding clinical acumen, early diagnosis is dependent on access to reliable serodiagnostic procedures, as well as on the discerning application and interpretation of these. In the case of RA, however, no disease-specific serodiagnostic procedure is available due to the multi-factorial and polygenic nature of this autoimmune disorder. This has resulted in the development of an array of serodiagnostic procedures based on the detection of autoantibodies reactive with various putative autoantigens. Other procedures based on measurement of elevations in the concentrations of systemic biomarkers of inflammation, most commonly acute phase reactants and cytokines/chemokines, are used as objective indices of disease activity. Following a brief overview of RA research in African populations, the current review is focused on those autoantibodies/biomarkers, specifically rheumatoid factor, anti-citrullinated peptide antibodies and C-reactive protein, which is the major topic of this review, preceded by a brief historical overview of RA research in Africa.
The primary aims of this review are: (1) to evaluate the utility of biomarkers published recently from data accrued from the African continent; (2) to assess the utility and cost-effectiveness of those biomarkers which improve the management of RA; and (3) to formulate recommendations in respect of optimising disease management in relation to laboratory testing.
Rheumatoid arthritis research in Africa
RA is a debilitating disease and has a severe impact on mobility and life expectancy of patients. This could be alleviated if patients were diagnosed early, enabling more accurate prediction of severe erosive disease, implementation of aggressive therapy and attainment of low disease activity. Early attainment of at least low disease activity is not only beneficial to the patient, but also has significant cost-saving implications [2] [3] [4] [5] . This has resulted in the search for reliable, affordable biomarkers with improved diagnostic and/or predictive potential.
Multiple biomarkers of disease activity in RA have been evaluated in studies originating from both Africa [6] [7] [8] [9] [10] [11] and elsewhere [12] [13] [14] [15] [16] . In addition, commercial ventures have also focused on developing multi-array test profiles that may improve cost-effective management of RA [15, 17] . However, estimating the cost of RA disease burden in the South African and continental African setting in general is lacking, with the majority of articles relating to this topic having been published prior to 1990 [18] . Exceptions include a 2009 study originating from Kenya which concluded that the majority of RA patients present at a relatively young age and are suboptimally treated, which impacts negatively on disease control and quality of life [19] , while a 2010 article highlighted the prevalence and functional impact of musculoskeletal conditions, including RA, in a small cohort in Cape Town [20] . Consequently, information is either wholly outdated or restricted to limited geographical regions.
In a systematic review published in 2012 by Dowman et al., assessing the burden of RA in Africa, the authors commented on the limited number of publications emanating from the continent. Of the initial 80 publications identified, only 10 reported on the prevalence of RA and these were limited to South Africa, Nigeria and Uganda. The authors concluded that the information was inadequate to guide national health policies with respect to RA [18] . With respect to innovations in diagnosis, a study from Cameroon reported that measurement of anti-citrullinated protein antibodies (ACPAs) was useful as a biomarker of RA and that the HLA-DRB1 shared epitope (SE), a genetic marker of disease susceptibility, was present in their RA population, but in lower frequency than in Caucasians. SE was also not a predictor of the presence of rheumatoid factor (RF) immunoglobulin M (IgM), RF immunoglobulin A (IgA) or ACPA using either of the second-or third-generation anti-cyclic citrullinated peptide (CCP) antibody tests [21] .
A recent study from South Africa has focused on identifying immunodiagnostic biomarkers, which if used in combination with clinical disease activity indices and socio-demographic features of the patients, optimise the management and outcome of newly diagnosed, DMARDnaïve RA patients with early disease.
In summary, the findings reported were as follows:
• RF, like ACPA, is significantly associated with erosive disease, smoking and functional disability. Combination testing of RF and ACPA had the best specificity and positive predictive value [22] • Systemic pro-inflammatory and anti-inflammatory cytokines were elevated in DMARD-naïve RA patients, some of which were strongly and positively correlated with RF, ACPA and acute phase reactants, as well as with high disease activity (HDA) [6] • Patients unresponsive to DMARDs after 6 months of treatment are unlikely to improve at 12 months of treatment, underscoring the need for better disease management to attain low disease activity (LDA) or remission earlier in disease [23] . A large proportion of indigenous South Africans suffering from RA still has substantial functional disability and suboptimal mental health despite being on DMARD therapy for 12 months. A need to further investigate interventions in support programmes and biological therapies in this population was identified [24] • The HLA-DRB1 SE has significant expression in the black South African RA population. Classification according to the Du Montcel's revised criteria [25] indicated an overexpression of high-risk alleles associated with elevated clinical and biomarkers linked with disease severity [7] • Rheumatoid nodules (RN), which were identified in 22.8 % of the RA cohort, were significantly associated with HDA, swollen joint counts (SJC) and radiographic scores, as well as with certain cytokines, but not RF and ACPA [24] • After 6 months of therapy, SDAI, ACPA and certain circulating cytokines were dramatically reduced in the cohort, indicating possible prognostic value of a select group of circulating cytokines when used in conjunction with ACPA [11] .
Rheumatoid factor (RF) and/or anti-citrullinated peptide antibodies (ACPAs)
The 2010 Rheumatoid Arthritis Classification Criteria, an American College of Rheumatology/European League against Rheumatism (ACR/EULAR) collaborative initiative, has incorporated rheumatoid factor (RF) and/or anticitrullinated protein antibody (ACPA) serological tests, for the first time, of which a score is assigned according to the positivity and level of either RF or ACPA results, which forms part of the scoring to contribute to the overall likelihood of diagnosing of RA [26] . RF was the first autoantibody described that was associated with RA. Scientists discovered that sera from RA patients agglutinated sheep red blood cells (SRBC) that were sensitised by rabbit antibodies. In 1940, the term "rheumatoid factor" was used when the correlation between the agglutination factor and RA was confirmed. RF antibodies are predominantly IgM (RF IgM), but may also be of the IgG and IgA classes. RF targets the Fc region of human IgG in the γ2-γ3 cleft. The resultant immune complexes contribute to the pathogenesis of RA via complement activation [27] .
The most common methods in use for RF detection are: (1) enzyme-linked immunosorbent assay (ELISA); (2) indirect agglutination using latex, charcoal or human red blood cells (RBC) as carrier particles loaded with IgG of human or rabbit origin; and (3) laser or rate nephelometry in which latex is coated with IgG (human) with the amount of light scatter caused by the RF IgG-coated latex bound by the RF IgM directly related to the concentration of RF [28] .
Although RF is present in a high percentage (>86 %) of RA patients, it is also present in other autoimmune diseases and infectious diseases, as well as in about 3-5 % of the healthy population, albeit at lower concentrations (<50 IU/ ml) [29, 30] . Transient increases in RF IgM are also part of the normal immune response and are detectable during infection in healthy individuals and especially in the elderly [31] . However, the persistence of RF in the setting of titres in excess of 50 or 100 IU/ml improves the specificity for RA to ≥88 and ≥95 %, respectively [32] .
It has also been reported that RF IgM and RF IgA in combination are almost exclusively found in RA patients and that distinguishing between RF single isotypes is more specific and sensitive than other detection methods [33] .
Classically, RF has been the most useful biomarker in the diagnosis of RA until the advent of ACPA [34] . Citrullination or deimination is the term used for the post-translational modification of the amino acid arginine in a protein via conversion to the amino acid citrulline. This reaction is mediated by enzymes known as peptidylarginine deiminases (PADs). The conversion of arginine to citrulline has significant consequences for the structure and function of proteins, since arginine is positively charged at neutral pH, whereas citrulline is uncharged. This increases the hydrophobicity of the protein, leading to changes in protein dimensional orientation [35] . Schellekens et al. described the existence of autoantibodies to filaggrin subunits which contained high numbers of arginine residues which were modified to citrulline by peptidylarginine deiminase in vitro. They also showed that these antibodies reacted with anti-perinuclear factor/antikeratin (APA/AKA) and demonstrated a strong correlation with the citrulline peptides, confirming that the citrullinated peptides represent the major epitopes recognised by APA/ AKA as seen by indirect immunofluorescence (IIF) using bucal mucosa cells [34] .
Van Boekel et al. [29] first demonstrated that ACPAs were detected early in disease and predicted erosive disease. In 2005, Rantapää-Dahlqvist concluded that measurement of ACPA is superior to RF in the early diagnosis of RA and is also a better indicator of disease severity [36] . The diagnostic and prognostic utility of measurement of ACPA was conclusively established by Van Boekel et al. in 2007 who established the specificity of ACPA for RA.
Recently, it was reported that ACPA titres decreased significantly after treatment with DMARDs in a therapy-naïve cohort of black South Africans diagnosed with RA and that the ACPA levels were statistically significantly higher in those positive for the high-risk HLA alleles associated with RA [11] .
Following confirmation of the association of ACPA with RA, a major review by Aggarwal et al. [37] which was focused on the application of ACPA as a diagnostic tool in respect of performance, precision correlation, cost-effectiveness and accuracy led to the following conclusions:
• ACPA assays have good predictive value because they are associated with the known genetic and epidemiologic risk factors for RA, and also identify a population of RA patients with more severe, erosive joint disease, who are at high risk for more rapid joint destruction • RF and ACPA are two different autoantibody systems and do not measure or reflect the same underlying biology • ACPA assays are becoming increasingly available and less expensive. Cost-effectiveness analyses suggest that testing of ACPA in patients presenting with undifferentiated arthritis is cost-effective, particularly in relation to eliminating the indirect costs associated with delayed diagnosis • ACPA offers similar sensitivity, but higher specificity, for RA than RF in early disease. When used in the identification of patients with subclinical RA, as well as those presenting with early undifferentiated symptoms, a high-risk population, the positive predictive value of the ACPA assay is in the order of 95 %.
• In the setting of a relatively high clinical suspicion (pretest probability) and a positive ACPA result, the patient has a high likelihood of having or developing RA. If ACPA is negative, further testing may be indicated depending on the level of clinical suspicion" [37] .
The combination of testing for both ACPA and RF to obtain a sensitivity >99 % is well known [38] and is reinforced by a study undertaken by Infantino et al. [39] which concluded that a combination of ACPA and RF IgM and IgA isotype testing delivers the best screening procedure for detection of early RA.
Other putative autoantigens associated with RA
Notwithstanding RF and ACPA, RA is associated with the presence of several other autoantibodies directed against different antigenic determinants.
Although measurement of anti-Sa (citrullinated vimentin), and nuclear ribonucleoprotein A2 and its splice variant B1 (hnRNP A2B1), also known as anti-RA33, as well as anti-mutated citrullinated vimentin (MCV) has been reported, their diagnostic utilities are significantly less than those of RF and ACPA. Anti-Sa has been shown to be associated with higher RF and ACPA values, as well as with HDA, but its overall sensitivity is lacking in comparison with RF and ACPA. Citrullinated vimentin has been detected in the synovium, consistent with a role for this putative autoantigen in the pathogenesis of RA [40, 41] .
Circulating antibodies against anti-RA33 have also been reported to be present in systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD) and RA and to be specific for the RNA binding domains of hnRNP-A2; however, as mentioned above, the overall sensitivity and specificity for RA is low (20-40 %) [42] .
Anti-MCV antibodies, although comparable to anti-CCP in specificity, lack prognostic value and have not gained significant traction to replace ACPA. Measurement of anti-MCV antibodies is, however, suggested as an alternative in the setting of negative results for RF and ACPA, and there is a strong clinical indication of RA [43] . In addition, these have varied sensitivity and prognostic values as summarised in Table 1 .
Anti-glucose-6-phosphate isomerase (GPI), anti-collagen, anti-BiPp68 (stress protein), anti-heat shock protein 90 (hsp90), anti-calpastatin, anti-α-enolase, anti-peptidylarginine deiminase, type IV (PAD4) antibodies have not demonstrated meaningful diagnostic or prognostic sensitivity or specificity for RA (also shown in Table 1 ).
C-reactive protein
C-reactive protein is an integral component of RA disease activity scores [disease activity score (DAS28)-CRP and Simplified Disease Activity Index (SDAI)] and multibiomarker disease activity algorithms, individually, or in conjunction with RF, ACPA and gender. Furthermore, persistently high CRP values in RA patients are associated with greater risk for progressive joint deterioration and are indicative of the need for more aggressive treatment, whereas a decrease in CRP values is indicative of an effective treatment regimen [44] . A retrospective study utilising sera from blood donors who were later diagnosed with RA demonstrated that elevated levels of CRP are evident several years before the appearance of clinical manifestations of disease activity and that these were independent of the presence of other RA-associated biomarkers [45] . It has been reported that CRP, in conjunction with ACPA, but not RF, remains elevated post-DMARDs treatment, especially in patients treated with combination therapy [methotrexate (MTX) and corticosteroids] when compared to patients on MTX monotherapy, supporting the contention that measurement of CRP in combination with ACPA has both diagnostic and prognostic potential in RA [11] .
Measurement of CRP in combination with RF, ACPA and HLA-DRB1-associated genes has also been shown to predict radiographic progression and improve the management of RA [46] [47] [48] .
Recommendations
Only limited budgets are often available to health providers in developing countries and often compete with priority programmes such as HIV and TB to curb high burdens of disease. Non-communicable diseases such as RA may therefore receive a lower than necessary priority requiring discerning choice of the most reliable and cost-effective laboratory diagnostic procedures. Those currently available procedures which have both diagnostic and prognostic potential are shown in Fig. 1 , together with their associated costs, advantages and limitations. Figure 2 indicates those biomarkers and their associated relevance to RA which can be tested for at different stages of disease progression. The flow begins with genetic markers to determine the possible predisposition of developing RA before clinical manifestation, together with possible environmental triggers. This is followed by detection of those biomarkers incorporated into the ACR/EULAR 2010 classification. These assist in both diagnosis and post-classification monitoring.
Realistically, however, RF and ACPA are the current cornerstones of RA diagnosis and when used in combination ensure the highest sensitivity and PPV. Other circulating biomarkers such as CRP in particular, and possibly certain cytokines when used in combination with RF and ACPA, may contribute to assessment of disease severity and outcome.
Given the ongoing severe financial constraints confronting national health budgets of developing countries, measurement of RF or ACPA on presentation is essential, preferably in combination, or, alternatively, RF only followed by ACPA according to clinical intuition.
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